Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Corvas begins phase Ia trial of rNAPc2

April 3, 1997

Menarini prepares thrombin inhibitors

April 3, 1997

New thrombin inhibitors from Novartis

April 3, 1997

VIMRx licenses factor IXa inhibitor from Columbia University

April 2, 1997

First generic warfarin product cleared by the FDA

April 1, 1997

Genzyme Transgenics receives further funding for development of transgenic ATIII

April 1, 1997

Terumo claims platelet aggregation/thromboxane synthase inhibitors

April 1, 1997

Antiplatelet 5-HT2A receptor antagonist characterized by Toa Eiyo

March 27, 1997

Novel orally active antithrombotic agent from Fuji Yakuhin

March 27, 1997

Biological role of CD39 uncovered by Immunex and collaborators

March 26, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....